Boston, MA 09/02/2014 (wallstreetpr) – biotechnology company, United Therapeutics Corporation (NASDAQ:UTHR) Chief Executive Officer, Martine Rothblatt, said that the ruling of the New Jersey District Court of the U.S. had validated its emphasis and the stand on the patents issue concerning Remodulin product.
CEO Comments
The company’s CEO said that the New Jersey Court ruling had only confirmed its validity and enforceability of the patent 117. He also said that it had always stressed that its investments in scientific advances and the consequential intellectual property would enable them to bring its products closer to patients. And the latest Court decision was only a validation of such stress, he said.
United Therapeutics Corporation (NASDAQ:UTHR) said that it was analyzing the Court’s ruling and evaluating its further steps in respect of the ‘007 patent. This may include an appeal against the ruling in the Federal Circuit’s U.S. Court of Appeals.
Court Ruling On Patent
On Friday, the company disclosed that the New Jersey District Court of the U.S. had given a ruling in favor of the company in a suit against Sandoz, Inc. on the patent issue relating to Remodulin product. The Judge, Peter Sheridan, said that the U.S. patent was not only valid but was also enforceable against Sandoz and charged Sandoz from marketing its generic version of the product till the patent expires in October 2017.
The U.S. Court had also given its verdict on the patent expiring in 2029 and found to be valid. However, it viewed that the patent would not be violated by Sandoz’ generic version of the product.
Sandoz Files ANDA
In December 2011, Sandoz had filed an Abbreviated New Drug Application or ANDA requiring approval to market generic version of Remodulin while challenging patents in relation to Remodulin as part of its ANDA. This had led United Therapeutics Corporation (NASDAQ:UTHR) to file a lawsuit against Sandoz and the subject in a Court of law.
